- Published on
Medicine – Thrombocytopenia
Thrombocytopenia is a haematological condition characterised by a circulating platelet count below 150 × 10⁹/L.
Platelets are essential for primary haemostasis. A reduction in platelet count increases the risk of mucocutaneous bleeding, including petechiae, purpura, epistaxis and gum bleeding.
Thrombocytopenia results from decreased platelet production, increased destruction or consumption, splenic sequestration, dilution, or laboratory artefact. Identifying the mechanism is essential because management differs substantially between causes.
1. Classification of Thrombocytopenia
| Severity | Platelet Count |
|---|---|
| Mild | 100–149 × 10⁹/L |
| Moderate | 50–99 × 10⁹/L |
| Severe | Below 50 × 10⁹/L |
| Very severe | Below 10 × 10⁹/L |
Spontaneous serious bleeding becomes more likely at very low platelet counts, particularly below 10 × 10⁹/L. However, bleeding risk also depends on platelet function, the underlying disease and other clinical factors.
2. Pathophysiology
The mechanisms of thrombocytopenia can be divided into four principal groups.
Simplified classification of thrombocytopenia mechanisms. Pseudothrombocytopenia is an artefact rather than true platelet depletion.
3. Decreased Platelet Production
Decreased platelet production occurs when the bone marrow is unable to produce sufficient platelets.
A. Bone Marrow Failure
Bone marrow failure may impair megakaryocyte production and cause thrombocytopenia.
Important Causes
- Acute leukaemia: Malignant blast cells replace normal haematopoietic tissue.
- Aplastic anaemia: Reduced production of all three blood cell lines.
- Myelodysplastic neoplasms: Ineffective and abnormal platelet production.
- Myelofibrosis: Marrow fibrosis disrupts normal haematopoiesis.
- Bone marrow infiltration: Lymphoma, multiple myeloma or metastatic carcinoma.
- Cytotoxic chemotherapy and radiotherapy: Suppression of bone marrow activity.
Thrombocytopenia due to marrow failure is often associated with anaemia or leukopenia.
B. Megaloblastic Anaemia
Vitamin B12 or folate deficiency impairs DNA synthesis and causes ineffective haematopoiesis.
Severe deficiency may result in thrombocytopenia or pancytopenia.
Characteristic Findings
- Macrocytosis.
- Macro-ovalocytes.
- Hypersegmented neutrophils.
- Reduced platelet count.
C. Other Causes of Reduced Production
- Chronic alcohol exposure.
- Certain medications.
- Viral infections affecting marrow function.
- Severe nutritional deficiencies.
- Inherited thrombocytopenia syndromes.
4. Increased Platelet Destruction
Increased platelet destruction may be immune-mediated or non-immune-mediated.
A. Immune Thrombocytopenia (ITP)
Immune thrombocytopenia (ITP), historically called immune thrombocytopenic purpura, is an acquired immune disorder characterised by increased platelet destruction and impaired platelet production.
Autoantibodies target platelet antigens, resulting in increased platelet clearance, particularly by the spleen.
Typical Clinical Findings
- Isolated thrombocytopenia.
- Petechiae and purpura.
- Easy bruising.
- Epistaxis or gum bleeding.
- Usually no significant splenomegaly.
ITP is a diagnosis of exclusion. Management depends on bleeding severity, platelet count and clinical circumstances.
Treatment Options
- Observation in selected patients.
- Corticosteroids.
- Intravenous immunoglobulin (IVIG).
- Thrombopoietin receptor agonists.
- Other second-line immune-directed therapies.
B. Viral Infections
Viral infections may cause thrombocytopenia through immune-mediated platelet destruction, marrow suppression or increased consumption.
Examples
- Dengue.
- HIV.
- Hepatitis C.
- Epstein–Barr virus.
- Cytomegalovirus.
C. Drug-Induced Thrombocytopenia
Certain medications may cause immune-mediated platelet destruction or bone marrow suppression.
Examples
- Heparin.
- Quinine.
- Some antibiotics.
- Certain anticonvulsants.
- Cytotoxic chemotherapy.
Heparin-Induced Thrombocytopenia (HIT)
HIT is a prothrombotic immune complication associated with antibodies against platelet factor 4–heparin complexes.
Important Features
- Platelet count often falls by more than 50% from baseline.
- Typically develops 5–10 days after heparin exposure.
- Earlier onset may occur with recent prior heparin exposure.
- Associated with thrombosis rather than predominantly bleeding.
- The 4Ts score helps estimate the pre-test probability.
Suspected HIT requires prompt assessment. When clinical probability is intermediate or high, heparin should be discontinued and appropriate non-heparin anticoagulation considered under specialist guidance while confirmatory testing is arranged.
D. Systemic Lupus Erythematosus (SLE)
SLE may cause immune-mediated thrombocytopenia through platelet-directed autoantibodies.
Associated manifestations may include:
- Arthritis.
- Skin rash.
- Nephritis.
- Autoimmune haemolytic anaemia.
E. Lymphoma
Lymphoma may cause thrombocytopenia through several mechanisms:
- Secondary immune thrombocytopenia.
- Bone marrow infiltration.
- Splenic enlargement and sequestration.
- Treatment-related marrow suppression.
5. Increased Platelet Consumption
A. Disseminated Intravascular Coagulation (DIC)
DIC is a systemic disorder involving widespread activation of coagulation, leading to consumption of platelets and clotting factors.
Common Causes
- Sepsis.
- Major trauma.
- Obstetric complications.
- Malignancy, particularly acute promyelocytic leukaemia.
Typical Laboratory Findings
- Thrombocytopenia.
- Prolonged PT and often aPTT.
- Elevated D-dimer.
- Reduced fibrinogen in severe cases.
- Schistocytes in some patients.
B. Thrombotic Microangiopathy
Thrombotic microangiopathies cause platelet consumption within small-vessel thrombi.
Important Examples
- Thrombotic thrombocytopenic purpura (TTP).
- Haemolytic uraemic syndrome (HUS).
Typical findings include:
- Thrombocytopenia.
- Microangiopathic haemolytic anaemia.
- Schistocytes on the peripheral blood film.
- Possible renal or neurological abnormalities.
Suspected TTP requires immediate haematology assessment and urgent treatment. Treatment should not be delayed while awaiting ADAMTS13 results when clinical suspicion is high.
6. Hypersplenism
Hypersplenism causes thrombocytopenia through increased splenic sequestration of platelets.
Important Causes
- Liver cirrhosis.
- Portal hypertension.
- Chronic liver disease.
- Haematological malignancies.
- Splenic infiltrative disorders.
Thrombocytopenia is often the earliest or most prominent cytopenia.
Unlike immune destruction, hypersplenism is primarily a problem of platelet distribution, although other mechanisms may coexist.
7. Platelet Aggregation and Pseudothrombocytopenia
Platelet clumping in a blood sample may cause an artificially low automated platelet count.
This is called pseudothrombocytopenia.
It may occur due to EDTA-dependent platelet aggregation in the collection tube.
Important Features
- The patient may have no bleeding symptoms.
- Peripheral blood film shows platelet clumps.
- Repeating the platelet count using an alternative anticoagulant, such as citrate, may help confirm the finding.
8. Clinical Features
Thrombocytopenia typically causes mucocutaneous bleeding, reflecting impaired primary haemostasis.
| Clinical Feature | Description |
|---|---|
| Petechiae | Small, non-blanching red or purple spots |
| Purpura | Larger areas of bleeding into the skin |
| Ecchymoses | Bruising |
| Epistaxis | Nosebleeds |
| Gum bleeding | Bleeding from the oral mucosa |
| Menorrhagia | Heavy menstrual bleeding |
| Gastrointestinal bleeding | May occur in severe cases |
| Intracranial haemorrhage | Rare but potentially life-threatening |
Deep muscle bleeding and haemarthroses are more characteristic of coagulation factor disorders than isolated thrombocytopenia.
9. Investigations
A. Full Blood Count
The full blood count confirms thrombocytopenia and determines whether it is isolated or accompanied by anaemia or leukopenia.
B. Peripheral Blood Film
| Blood Film Finding | Possible Diagnosis |
|---|---|
| Isolated low platelets, otherwise normal film | ITP |
| Platelet clumps | Pseudothrombocytopenia |
| Schistocytes | TTP, HUS, DIC or another fragmentation process |
| Circulating blasts | Acute leukaemia |
| Macro-ovalocytes and hypersegmented neutrophils | Megaloblastic anaemia |
| Dysplastic blood cells | Myelodysplastic neoplasm |
| Large or giant platelets | ITP or inherited macrothrombocytopenia |
C. Coagulation Profile
PT, aPTT, fibrinogen and D-dimer may help identify DIC or other coagulation abnormalities.
Coagulation studies are often normal in uncomplicated ITP and TTP.
D. Additional Investigations
- Liver and renal function tests.
- Vitamin B12 and folate.
- HIV, hepatitis and other viral testing when indicated.
- Autoimmune investigations.
- Haemolysis markers.
- HIT testing when indicated.
- ADAMTS13 activity when TTP is suspected.
- Bone marrow examination when a marrow disorder is suspected.
10. Diagnostic Approach
11. Management
Treatment is directed at the underlying cause rather than the platelet count alone.
| Cause | General Management |
|---|---|
| ITP | Observation or immune-directed treatment depending on bleeding risk |
| HIT | Stop heparin and initiate appropriate non-heparin anticoagulation |
| DIC | Treat the underlying trigger and provide haemostatic support when indicated |
| TTP | Urgent plasma exchange-based specialist treatment |
| Megaloblastic anaemia | Vitamin B12 or folate replacement as appropriate |
| Marrow failure | Disease-specific treatment and supportive care |
| Hypersplenism | Treat the underlying disorder |
| Pseudothrombocytopenia | Confirm the true platelet count; no treatment for the artefact |
Platelet Transfusion
Platelet transfusions may be indicated for severe bleeding or selected high-risk situations.
They are not routinely appropriate for all causes of thrombocytopenia, particularly suspected HIT or TTP, where management requires disease-specific assessment.
12. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Definition | Platelets below 150 × 10⁹/L |
| Reduced production | Leukaemia, aplastic anaemia, megaloblastic anaemia |
| Immune destruction | ITP, SLE, drug-induced thrombocytopenia |
| Heparin-associated | HIT, a prothrombotic condition |
| Platelet consumption | DIC, TTP, HUS |
| Splenic sequestration | Hypersplenism |
| Laboratory artefact | EDTA-related platelet clumping |
| Typical bleeding | Petechiae, purpura, mucosal bleeding |
| Key investigation | FBC and peripheral blood film |
| Schistocytes | Consider microangiopathic haemolysis |
| Isolated thrombocytopenia | Consider ITP after excluding other causes |
13. Key Examination Pearls
- Thrombocytopenia is defined as a platelet count below 150 × 10⁹/L.
- Decreased platelet production occurs in marrow failure and megaloblastic anaemia.
- ITP typically presents with isolated thrombocytopenia.
- HIT is associated with thrombosis despite a reduced platelet count.
- SLE and lymphoma may cause secondary immune thrombocytopenia.
- DIC and thrombotic microangiopathies cause platelet consumption.
- Hypersplenism causes platelet sequestration.
- Platelet clumping can produce pseudothrombocytopenia.
- Schistocytes with thrombocytopenia raise concern for microangiopathic haemolysis.
- A peripheral blood film is essential in evaluating an unexplained low platelet count.
Thrombocytopenia with an otherwise normal blood film suggests possible ITP; thrombocytopenia with schistocytes suggests microangiopathic haemolysis; and thrombocytopenia with anaemia and leukopenia suggests a possible bone marrow disorder.
Thrombocytopenia accompanied by active major bleeding, neurological symptoms, suspected TTP, suspected HIT with thrombosis or other signs of serious illness requires urgent medical assessment.
Kembara Xtra – Medicine Revision Notes